Weill Medical College of Cornell University: Leukemia trials

The registry lists 11 Leukemia studies with Weill Medical College of Cornell University as lead sponsor. 0 are open to participants now and 5 have results posted.

Phase 1 5Phase 2 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Investigator Initiated Trial of CPX-351 for Untreated Acute Myeloid LeukemiaCompletedNCT03335267Phase 2Results posted
• Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AMLTerminatedNCT02532010Phase 2Results posted
• IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During Induction of High Risk LeukemiaTerminatedNCT02508324Phase 2Results posted
• Stem Cell Monitoring for CML Patients Undergoing Nilotinib TherapyCompletedNCT02353728Phase 2Results posted
• Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic MalignanciesTerminatedNCT01745913Phase 2Results posted
• CPX-351+GO in Subjects 55 Years Old, or Older, With AMLTerminatedNCT03878927Phase 1
• CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic SyndromeCompletedNCT03393611Phase 1
• Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML)CompletedNCT01352650Phase 1
• A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML)CompletedNCT00875693Phase 1
• Phase I Epigenetic Priming Using Decitabine With Induction Chemotherapy in AMLCompletedNCT00538876Phase 1
• Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDSCompletedNCT00195000Phase 2